EE05420B1 - Fentanli kompositsioon ninasiseseks manustamiseks - Google Patents

Fentanli kompositsioon ninasiseseks manustamiseks

Info

Publication number
EE05420B1
EE05420B1 EEP200300050A EEP200300050A EE05420B1 EE 05420 B1 EE05420 B1 EE 05420B1 EE P200300050 A EEP200300050 A EE P200300050A EE P200300050 A EEP200300050 A EE P200300050A EE 05420 B1 EE05420 B1 EE 05420B1
Authority
EE
Estonia
Prior art keywords
fentanyl
administration
intranasal administration
results
action
Prior art date
Application number
EEP200300050A
Other languages
English (en)
Estonian (et)
Inventor
Grarup Jesper
Wulff Nielsen Hanne
Original Assignee
Nycomed Danmark A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8159630&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE05420(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Nycomed Danmark A/S filed Critical Nycomed Danmark A/S
Publication of EE200300050A publication Critical patent/EE200300050A/xx
Publication of EE05420B1 publication Critical patent/EE05420B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EEP200300050A 2000-07-31 2001-07-31 Fentanli kompositsioon ninasiseseks manustamiseks EE05420B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200001154 2000-07-31
PCT/DK2001/000521 WO2002009707A1 (en) 2000-07-31 2001-07-31 Fentanyl composition for nasal administration

Publications (2)

Publication Number Publication Date
EE200300050A EE200300050A (et) 2004-12-15
EE05420B1 true EE05420B1 (et) 2011-06-15

Family

ID=8159630

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200300050A EE05420B1 (et) 2000-07-31 2001-07-31 Fentanli kompositsioon ninasiseseks manustamiseks

Country Status (24)

Country Link
US (3) US8017627B2 (sl)
EP (3) EP2255806A3 (sl)
JP (2) JP4898073B2 (sl)
KR (2) KR20080053423A (sl)
CN (2) CN100346788C (sl)
AT (1) ATE388705T1 (sl)
AU (2) AU8174601A (sl)
CA (1) CA2417727C (sl)
CY (2) CY1107405T1 (sl)
DE (2) DE60133203T3 (sl)
DK (2) DK1307194T4 (sl)
EA (1) EA006384B1 (sl)
EE (1) EE05420B1 (sl)
ES (2) ES2427976T5 (sl)
HK (1) HK1089106A1 (sl)
IL (2) IL154041A0 (sl)
IS (1) IS2803B (sl)
NO (2) NO330565B1 (sl)
NZ (1) NZ524396A (sl)
PL (1) PL207845B1 (sl)
PT (2) PT1307194E (sl)
SI (2) SI1307194T2 (sl)
UA (2) UA77398C2 (sl)
WO (1) WO2002009707A1 (sl)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040115133A1 (en) * 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
ES2427976T5 (es) 2000-07-31 2022-04-13 Takeda Pharma As Composición de sal de fentanilo para administración nasal
US20020106407A1 (en) * 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
US20090281023A9 (en) * 2001-06-04 2009-11-12 Nobex Corporation Mixtures Of Calcitonin Drug-Oligomer Conjugates And Methods Of Use In Pain Treatment
DE10141650C1 (de) * 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
GB0210264D0 (en) * 2002-05-03 2002-06-12 Arakis Ltd The treatment of pain and migraine headache
GB0300531D0 (en) * 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
GB0305579D0 (en) * 2003-03-11 2003-04-16 Dallas Burston Ltd Pharmaceutical compositions
GB0315632D0 (en) 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
US20070053965A1 (en) * 2005-02-25 2007-03-08 Gruenenthal Gmbh Kit comprising a plaster, optionally containing an active substance, and an agent that at least partially reduces skin irritation
US9289583B2 (en) 2006-01-06 2016-03-22 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8865743B2 (en) 2006-01-06 2014-10-21 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US9066847B2 (en) 2007-01-05 2015-06-30 Aceirx Pharmaceuticals, Inc. Storage and dispensing devices for administration of oral transmucosal dosage forms
US8753308B2 (en) 2006-01-06 2014-06-17 Acelrx Pharmaceuticals, Inc. Methods for administering small volume oral transmucosal dosage forms using a dispensing device
US8252328B2 (en) * 2006-01-06 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8535714B2 (en) 2006-01-06 2013-09-17 Acelrx Pharmaceuticals, Inc. Small volume oral transmucosal dosage forms containing sufentanil for treatment of pain
US8252329B2 (en) 2007-01-05 2012-08-28 Acelrx Pharmaceuticals, Inc. Bioadhesive drug formulations for oral transmucosal delivery
US8357114B2 (en) 2006-01-06 2013-01-22 Acelrx Pharmaceuticals, Inc. Drug dispensing device with flexible push rod
US8202535B2 (en) * 2006-01-06 2012-06-19 Acelrx Pharmaceuticals, Inc. Small-volume oral transmucosal dosage forms
NZ610790A (en) * 2006-04-13 2015-05-29 Nupathe Inc Transdermal methods and systems for the delivery of anti-migraine compounds
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
US10512644B2 (en) 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2009070829A1 (en) * 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration
EP2247330B1 (en) 2008-02-07 2017-09-20 The University of Washington Circumferential aerosol device
GB2464282A (en) * 2008-10-08 2010-04-14 Archimedes Dev Ltd A device for administering a dose of opioid analgesic
US8945592B2 (en) 2008-11-21 2015-02-03 Acelrx Pharmaceuticals, Inc. Sufentanil solid dosage forms comprising oxygen scavengers and methods of using the same
DE102009001041A1 (de) * 2009-02-20 2010-08-26 Marien-Apotheke Fulda Ohg Notfallset zur Herstellung eines Arzneimittels zur nasalen Anwendung von Opioiden bei Atemnot
US20130142868A1 (en) 2010-08-20 2013-06-06 University Of Washington Circumferential Aerosol Device for Delivering Drugs to Olfactory Epithelium and Brain
ES2592259T3 (es) 2011-02-04 2016-11-29 Archimedes Development Limited Contenedor mejorado
EP3679971B1 (en) 2011-03-03 2022-07-27 Impel Pharmaceuticals Inc. Nasal drug delivery device
EP3851142A1 (en) 2011-05-09 2021-07-21 Impel NeuroPharma Inc. Nozzles for nasal drug delivery
RU2587051C2 (ru) * 2011-05-13 2016-06-10 Эро-Селтик С.А. Интраназальные фармацевтические дозированные формы, содержащие налоксон
EP2991713B1 (en) 2013-04-28 2019-06-19 Impel Neuropharma Inc. Medical unit dose container
SG11201704797TA (en) 2014-12-23 2017-07-28 Acelrx Pharmaceuticals Inc Systems, devices and methods for dispensing oral transmucosal dosage forms
US11266799B2 (en) 2015-09-10 2022-03-08 Impel Neuropharma, Inc. In-line nasal delivery device
WO2019104205A1 (en) 2017-11-21 2019-05-31 Impel Neuropharma, Inc. Intranasal device with dip tube
JP2021503988A (ja) 2017-11-21 2021-02-15 インペル ニューロファーマ インコーポレイテッド インレットインターフェースを用いた鼻腔内装置
WO2019136308A1 (en) 2018-01-05 2019-07-11 Impel Neuropharma, Inc. Intranasal delivery of olanzapine by precision olfactory device
BR112020013744A8 (pt) 2018-01-05 2022-10-18 Impel Neuropharma Inc Dispensação intranasal de di-hidroergotamina por dispositivo olfativo de precisão
WO2020018959A1 (en) 2018-07-19 2020-01-23 Impel Neuropharma, Inc. Respiratory tract delivery of levodopa and dopa decarboxylase inhibitor for treatment of parkinson's disease
BR112021013244A8 (pt) 2019-01-03 2022-10-18 Impel Neuropharma Inc Dispositivo de entrega de fármaco nasal
JP2022532259A (ja) 2019-05-17 2022-07-13 インペル ファーマシューティカルズ インコーポレイテッド 使い捨ての鼻腔内送達デバイス
WO2022038403A1 (ru) 2020-10-15 2022-02-24 Владимир ТИМКО Фармацевтическая композиция на основе налбуфина и/или его солей для назального применения

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4464378A (en) * 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4486423A (en) * 1983-04-21 1984-12-04 Janssen Pharmaceutica Inc. Stable fentanyl composition
US4588580B2 (en) 1984-07-23 1999-02-16 Alaz Corp Transdermal administration of fentanyl and device therefor
FR2568773B1 (fr) * 1984-08-10 1989-03-03 Sandoz Lab Nouvelles compositions pharmaceutiques administrables par voie nasale
US4806341A (en) 1985-02-25 1989-02-21 Rutgers, The State University Of New Jersey Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
US5122127A (en) * 1985-05-01 1992-06-16 University Of Utah Apparatus and methods for use in administering medicaments by direct medicament contact to mucosal tissues
ZA875317B (en) 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4916142A (en) 1987-02-02 1990-04-10 Boc, Inc. N-heterocyclic-N-(4-piperidinyl)amides and pharmaceutical compositions and their use as analgesics
GB8900267D0 (en) † 1989-01-06 1989-03-08 Riker Laboratories Inc Narcotic analgesic formulations and apparatus containing same
US5019583A (en) 1989-02-15 1991-05-28 Glaxo Inc. N-phenyl-N-(4-piperidinyl)amides useful as analgesics
US5028616A (en) 1989-09-05 1991-07-02 G. D. Searle & Co. N-benzylpiperidine amides
US5098915A (en) 1989-09-05 1992-03-24 G. D. Searle & Co. Substituted N-benzylpiperidine amides
ES2117642T3 (es) 1990-05-10 1998-08-16 Bechgaard Int Res Preparado farmaceutico que contiene n-glicofuroles y n-etilen glicoles.
WO1994010987A1 (en) 1992-11-09 1994-05-26 Pharmetrix Corporation Combined analgesic delivery methods for pain management
US5507277A (en) † 1993-01-29 1996-04-16 Aradigm Corporation Lockout device for controlled release of drug from patient-activateddispenser
US5466700A (en) 1993-08-30 1995-11-14 Glaxo Wellcome Inc. Anesthetic use of N-phenyl-N-(4-piperidinyl)amides
US5739135A (en) 1993-09-03 1998-04-14 Bristol-Myers Squibb Company Inhibitors of microsomal triglyceride transfer protein and method
US5543434A (en) 1994-02-25 1996-08-06 Weg; Stuart L. Nasal administration of ketamine to manage pain
GB9404945D0 (en) 1994-03-15 1994-04-27 Glaxo Group Ltd Pharmaceutical composition
USRE38407E1 (en) 1994-03-23 2004-01-27 Delex Therapeutics Inc. Pain management with liposome-encapsulated analgesic drugs
CA2189351C (en) * 1994-05-13 2008-12-30 Stephen J. Farr Narcotic containing aerosol formulation
US5958379A (en) 1994-09-30 1999-09-28 Mika Pharma Gesellschaft Fuer Die Entwicklung Und Vermarktung Pharmazeutischer Producte Mbh Pharmaceutical composition
ATE263597T1 (de) 1995-06-05 2004-04-15 Alza Corp Vorrichtung zur transdermalen iontophoretischen verabreichung von fentanyl und sufentanil
IE960375A1 (en) 1995-06-05 1996-12-11 Alza Corp Device for transdermal electrotransport delivery of fentanyl¹and sufentanil
US6881208B1 (en) 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
DE69637920D1 (de) * 1995-06-07 2009-06-18 Oneil Alexander G B Vom Patienten gesteuerte Vorrichtung zur Arzneimittelabgabe
AUPN603895A0 (en) 1995-10-19 1995-11-09 University Of Queensland, The Production of analgesic synergy by co-administration of sub-analgesic doses of two strong opioids
US6017963A (en) * 1995-11-14 2000-01-25 Euro-Celtique, S.A. Formulation for intranasal administration
US6787149B1 (en) 1996-12-12 2004-09-07 El Khoury And Stein Ltd. Topical application of opioid analgesic drugs such as morphine
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
GB9707934D0 (en) 1997-04-18 1997-06-04 Danbiosyst Uk Improved delivery of drugs to mucosal surfaces
US6143278A (en) 1998-02-23 2000-11-07 Elkhoury; George F. Topical application of opioid analgesic drugs such as morphine
SE9803239D0 (sv) 1998-09-24 1998-09-24 Diabact Ab Composition for the treatment of acute pain
SE9803240D0 (sv) 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
US6608073B1 (en) 1998-10-14 2003-08-19 New Millennium Pharmaceutical Research, Inc. Intranasal codeine for the rapid suppression of cough and rapid relief of pain
GB9823246D0 (en) 1998-10-24 1998-12-16 Danbiosyst Uk A nasal drug delivery composition
US6660715B2 (en) 1998-11-19 2003-12-09 Massachusetts Institute Of Technology Nonaqueous solutions and suspensions of macromolecules for pulmonary delivery
US7074388B2 (en) 1998-12-10 2006-07-11 Kos Life Science, Inc. Water stabilized medicinal aerosol formulation
AU2879100A (en) † 1999-02-12 2000-08-29 Miles A. Libbey Iii Formulation and system for intra-oral delivery of pharmaceutical agents
US6680071B1 (en) 1999-03-03 2004-01-20 R. P. Scherer Technologies, Inc. Opioid agonist in a fast dispersing dosage form
US6541021B1 (en) * 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
US6677332B1 (en) 1999-05-25 2004-01-13 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
DE60044134D1 (de) 1999-08-26 2010-05-20 Takeda Pharmaceutical Nasenschleimhaut haftende matrix
US7074803B2 (en) 2001-03-02 2006-07-11 Durect Corporation Opioid formulations
AU2001262992A1 (en) 2000-05-10 2002-02-18 University Of Kentucky Research Foundation System and method for intranasal administration of opioids
US20040115133A1 (en) 2000-05-10 2004-06-17 Wermeling Daniel P. Intranasal opioid compositions
US7049326B2 (en) 2000-05-12 2006-05-23 The University Of Toledo Method and compositions for temporarily incapacitating subjects
WO2001092226A1 (en) 2000-05-25 2001-12-06 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
EP1296649A2 (en) 2000-06-22 2003-04-02 Pharmasol Limited Pharmaceutical compositions comprising an opioid analgesic
US20020013331A1 (en) 2000-06-26 2002-01-31 Williams Robert O. Methods and compositions for treating pain of the mucous membrane
ES2427976T5 (es) 2000-07-31 2022-04-13 Takeda Pharma As Composición de sal de fentanilo para administración nasal
US20020106407A1 (en) 2000-12-11 2002-08-08 Dennis Coleman Method and apparatus for treating breakthrough pain
DE10064219B9 (de) 2000-12-22 2009-02-12 Nasalis Pain Relief International Gmbh Neue Fentanyl und/oder dessen Derivate enthaltende pharmazeutische Zusammensetzung zur nasalen Anwendung
JP4850346B2 (ja) 2001-03-15 2012-01-11 救急薬品工業株式会社 粘膜貼付剤
US20020187996A1 (en) 2001-05-14 2002-12-12 Dewey Stephen L. Prevention of addiction in pain management
FR2829757B1 (fr) * 2001-09-20 2004-07-09 Commissariat Energie Atomique Procede de preparation d'un sol stable de zircono-titanate de plomb et procede de preparation de films a partir dudit sol
CN1674903A (zh) 2002-07-11 2005-09-28 大鹏药品工业株式会社 经鼻吸收用组合物
US6946150B2 (en) 2002-08-14 2005-09-20 Gw Pharma Limited Pharmaceutical formulation
US20040102476A1 (en) 2002-11-25 2004-05-27 Chan Tai Wah High concentration formulations of opioids and opioid derivatives
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
US20060062812A1 (en) 2003-03-11 2006-03-23 Calvin Ross Novel compositions
SI1638933T1 (sl) 2003-06-17 2008-10-31 Pfizer Derivati N-pirolidin-3-il-amida kot inhibitorji ponovnega privzema serotonina in noradrenalina
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
GB0514043D0 (en) 2005-07-08 2005-08-17 Arakis Ltd Fentanyl formulation
SI1976521T1 (sl) 2006-01-25 2015-06-30 Insys Therapeutics, Inc. Podjezično fentanilno pršilo
WO2009047779A2 (en) 2007-06-20 2009-04-16 Nikki Nikhilesh Singh Composition containing fentanyl base aromatic oils and alkyl salicylate for the delivery of fentanyl base in vapour form
WO2009017837A2 (en) 2007-08-02 2009-02-05 Insys Therapeutics Inc. Sublingual fentanyl spray
WO2009070829A1 (en) 2007-12-05 2009-06-11 Krius Pty Ltd Non-aqueous oil-based fentanyl compositions for transmucosal administration

Also Published As

Publication number Publication date
EA006384B1 (ru) 2005-12-29
PT1307194E (pt) 2008-05-27
EE200300050A (et) 2004-12-15
ES2302742T5 (es) 2011-10-10
UA77398C2 (en) 2006-12-15
CN1466455A (zh) 2004-01-07
CN100346788C (zh) 2007-11-07
US20040034059A1 (en) 2004-02-19
PL365053A1 (en) 2004-12-27
DE60133203T3 (de) 2012-02-23
PT1642578E (pt) 2013-09-30
ES2427976T3 (es) 2013-11-05
SI1642578T2 (sl) 2022-01-31
KR20080053423A (ko) 2008-06-12
US20110281914A1 (en) 2011-11-17
CN101181241A (zh) 2008-05-21
PL207845B1 (pl) 2011-02-28
UA89755C2 (ru) 2010-03-10
DE60133203D1 (de) 2008-04-24
DK1307194T3 (da) 2008-07-14
JP4898073B2 (ja) 2012-03-14
IS2803B (is) 2012-09-15
CY1114645T1 (el) 2016-10-05
NZ524396A (en) 2003-09-26
US8017627B2 (en) 2011-09-13
EP2255806A2 (en) 2010-12-01
ES2302742T3 (es) 2008-08-01
KR100888275B1 (ko) 2009-03-10
NO20030365D0 (no) 2003-01-24
EP1307194A1 (en) 2003-05-07
EA200300201A1 (ru) 2003-06-26
AU8174601A (en) 2002-02-13
EP1307194B2 (en) 2011-04-27
US8158651B2 (en) 2012-04-17
US20070134164A1 (en) 2007-06-14
EP2255806A3 (en) 2011-06-29
JP2008044951A (ja) 2008-02-28
ATE388705T1 (de) 2008-03-15
ES2427976T5 (es) 2022-04-13
JP2004505052A (ja) 2004-02-19
IL154041A (en) 2011-05-31
IS6702A (is) 2003-01-28
EP1642578B2 (en) 2021-11-03
AU2001281746C1 (en) 2010-09-09
CA2417727C (en) 2009-09-01
DE20122843U1 (de) 2008-06-26
SI1307194T1 (sl) 2008-08-31
DK1307194T4 (da) 2011-07-18
AU2001281746B2 (en) 2006-10-05
EP1307194B1 (en) 2008-03-12
EP1642578A3 (en) 2006-09-27
CA2417727A1 (en) 2002-02-07
CY1107405T1 (el) 2012-12-19
DE60133203T2 (de) 2009-04-30
SI1642578T1 (sl) 2013-10-30
KR20030034126A (ko) 2003-05-01
HK1089106A1 (en) 2006-11-24
US8653107B2 (en) 2014-02-18
SI1307194T2 (sl) 2011-07-29
NO20110342L (no) 2003-03-31
NO20030365L (no) 2003-03-31
WO2002009707A1 (en) 2002-02-07
EP1642578A2 (en) 2006-04-05
DK1642578T3 (da) 2013-08-12
IL154041A0 (en) 2003-07-31
NO330565B1 (no) 2011-05-16
NO333809B1 (no) 2013-09-23
EP1642578B1 (en) 2013-07-03

Similar Documents

Publication Publication Date Title
EE05420B1 (et) Fentanli kompositsioon ninasiseseks manustamiseks
DK1458388T3 (da) En flydende farmaceutisk formulering omfattende nikotin til administrering i mundhulen
DK0831827T3 (da) Nye formuleringer til transdermal levering af pergolid
DK1346041T3 (da) Terapeutiske midler og fremgangsmåder til anvendelse deraf til behandling af en amyloidogen sygdom
EE200400020A (et) Asendatud oksasolidinoonid kombineeritud raviks
NO20032111L (no) Nye medikamentblandinger basert pa tiotropium-salter og pa salmeterol-salter
ATE400258T1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
ATE364595T1 (de) Pyridoxin- und pyridoxalanaloga als cardiovasculäre therapeutika
IL188176A0 (en) Stable pharmaceutical composition comprising linezolid form iv
WO2007123511A3 (en) Dosing regimens for the treatment of cancer
HUP0203197A2 (hu) Docetaxel alkalmazása hepatocelluláris karcinómák kezelésére
WO2004007676A3 (en) Combination therapy for the treatment of neoplasms
NO20054034L (no) Fremgangsmate for behandling av hypotyroidisme.
ATE473001T1 (de) Suchtpraevention in der schmerzbehandlung mit gamma vinyl gaba
SE0203817D0 (sv) New composition
TW200514582A (en) Transdermal preparation and method for reducing side effect in pergolide therapy
ATE452639T1 (de) Arzneimittelkompositionen aus tiotropiumsalzen und epinastin zur therapie von atemswegserkrankungen
EP1011672A4 (en) CONNECTIONS WITH ANALGETIC EFFECT AND COMPILATIONS THAT CONTAIN THEM

Legal Events

Date Code Title Description
HC1A Change of owner name
HC1A Change of owner name
HC1A Change of owner name